Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

Published:2004-04 Issue:4 Volume:34 Page:632-638
ISSN:0954-7894
Container-title:Clinical Experimental Allergy
language:en
Short-container-title:Clin Exp Allergy

Author:

Holgate S. T.,Chuchalin A. G.,Hebert J.,Lotvall J.,Persson G. B.,Chung K. F.,Bousquet J.,Kerstjens H. A.,Fox H.,Thirlwell J.,Cioppa G. Della,

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2222.2004.1916.x/fullpdf

Reference26 articles.

1. Costs of asthma according to the degree of severity

2. Difficult/therapy‐resistant asthmaThe need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies

3. The role of allergy in the development of asthma

4. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma

5. The epidemic of allergy and asthma

Cited by 450 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing the Asthma Phenotype of Military Personnel;Military Medicine;2024-08-19

2. Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial;Frontiers in Immunology;2024-07-29

3. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials;European Respiratory Review;2024-04-24

4. The Incredible Adventure of Omalizumab;International Journal of Molecular Sciences;2024-03-06

5. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3